Elan shares nose dive as drug linked to brain disease

Shares in the pharmaceutical group Elan have collapsed 45% in New York after the company issued information of two new cases of a potentially deadly brain disease arising from the use of its multiple sclerosis drug Tysabri.

The drug was withdrawn from the market in 2005 when the side-effect was discovered during trials. Today more than 31,000 people use the drug.